Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
Status:
RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
This is a an open-label, multi-center, single-arm study to evaluate the efficacy and safety of sonrotoclax, zanubrutinib and CD20mab in untreated MCL patients.
Phase:
PHASE2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital